Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies

INTRODUCTION: Immuno-oncology therapies, including immune checkpoint inhibitors (ICIs), have transformed cancer care and have brought into question whether classic oncology efficacy assessments adequately describe the distinctive responses observed with these agents. With more ICI-based therapies be...

Descripción completa

Detalles Bibliográficos
Autores principales: Michielin, Olivier, Lalani, Aly-Khan, Robert, Caroline, Sharma, Padmanee, Peters, Solange
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796265/
https://www.ncbi.nlm.nih.gov/pubmed/35078922
http://dx.doi.org/10.1136/jitc-2021-003024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796265/
https://www.ncbi.nlm.nih.gov/pubmed/35078922
http://dx.doi.org/10.1136/jitc-2021-003024

Ejemplares similares